Kumar Dhanasekharan, Ph.D. Senior Director at Amicus Therapeutics

Process Intensification                                                                                                                                                                                                                                                                                                                                                                     

Development of Next Generation Purification Platforms through Novel Technologies and Holistic Process Engineering Approaches. Speakers would address process intensification as part of next generation bioprocess strategy. In the current environment of diverse product pipelines, rapidly fluctuating market demands and growing competition from biosimilars, companies are driven to develop innovative solutions for highly flexible and cost‐effective processes and manufacturing. To address these challenging demands, integrated continuous processing, comprised of high‐density perfusion cell culture and a directly coupled with continuous capture step, can be used as a universal Biomanufacturing platform.                                                                                                                                                                                                                                                                                                                       

Area of Focus

1. Integrating new technology with existing manufacturing processes
2. Significant cost savings and other benefits
3. Applying new technology to a wide range of applications
4. Examples of how new strategies for recombinant purification have enabled process intensification

Confirmed Speakers: 

Kumar Dhanasekharan - Amicus Therapeutics

Alexei Voloshin - 3M

Hiren Ardeshna - GSK 

Andrew Tustian - Regeneron 

Antonio Ubiera - GSK 

Rajesh Beri - Lonza

Sigma Mostafa - KBI 

Benoit Mothes - Sanofi